Acceliant Releases Acceliant 6.1 after Successful R&D Partnership with REGISTRAT-MAPI
11 Oct, 2010
October 11 2010, Herndon, Virginia - REGISTRAT-MAPI and Acceliant are pleased to announce a further strengthening of their relationship via the release of Acceliant V6.1. REGISTRAT-MAPI has utilized Acceliant since 2007 for many of their Late Phase clinical studies. Acceliant V6.1, released earlier this year incorporates a number of groundbreaking functional enhancements and a new UI architecture, identified by REGISTRAT-MAPI, based on their unique experiences as the industry's largest leading global clinical research organization (CRO) dedicated solely to 'real life' late phase clinical research, and Acceliant users.
Stephen Webb, REGISTRAT-MAPI, President North America stated that the collaborative relationship with Acceliant, 'allows us to offer our clients innovative technologies and cutting-edge EDC specifically customized for late phase studies. With Acceliant and their dedicated team of EDC development professionals, our biometrics team's eCRF development expertise, and by listening to our clients' needs, REGISTRAT-MAPI can deliver 'world class' Late Phase research services and solutions.'
Acceliant 6.1 is a comprehensive, full life cycle e-Clinical Trials EDC platform comprised of Clinical Data Management, regulatory compliant Document Management, core Trial Management facilitating collaboration and site management, and rich business intelligence capabilities. What makes Acceliant unique is a proprietary Accelerated Trial Builder, which allows non-technical users to accomplish end-to-end configuration and build of a trial without the need for any programming. The Accelerated Trial Builder enables users to define data-fields, edit checks, code lists, complete CRF layouts, validate the build and then deploy the trial with a single click.
Based on an integrated design and architecture, all Acceliant modules and features have been designed and built as a single native platform. Version 6.1 includes technology-driven usability features that are beneficial when working with large trials involving thousands of sites and patients; several design improvements for efficiently handling large scale data sets; powerful capabilities for import/export of large data sets; and rapid edit and validation of test data. These enhancements provide benefits for all trial phases.
Commenting on the relationship, Sri Manchala, President and CEO of Acceliant, adds, 'Acceliant continues our commitment as a client-oriented organization and our partnership with REGISTRAT-MAPI is a culmination of over 10 years of dedication to the clinical trials solution industry. Acceliant is an industry leading tool enabling biopharmaceutical companies to decrease time to market, integrate data and processes, and address regulatory requirements.' Mr. Manchala further added, 'The ultimate goal of Acceliant is to deliver speed and productivity in EDC for CROs, Biopharmaceutical and Medical Device companies worldwide. As such, Acceliant will positively impact their clinical trial management operations to make them more business intelligent, efficient and cost effective in a rapidly changing healthcare industry'.
REGISTRAT-MAPI and Acceliant are collaborating in an R&D model for the benefit of the industry at large and will continue to share successful developments in future.
About Acceliant eClinical Suite
Acceliant eClinical Suite is competitive in meeting the challenges of today's dynamic market conditions. The Acceliant eClinical Suite is a pre-eminent offering that continues its 11-year history of providing innovative solutions for the life sciences industry. The Acceliant eClinical Suite is robust, scalable, and flexible. It has been proven by more than 350 Phase I-IV trials, covering all therapeutic areas and medical device trials. Engineered for agility, our service model differentiators enable us to implement and deploy in response to the data, functional, and analytic needs of clinical trials.